Positive data with belinostat and 5-FU for colorectal cancer presented at ASCO GI 17 January 2009

- This study indicates that the treatment can be targeted to a selected group
of patients who can benefit from the treatment 
with belinostat and 5-FU (BelFU) -

Copenhagen, Denmark, 19 January 2008 - TopoTarget A/S (OMX: TOPO) announces
that at the ASCO GI conference (American Society of Clinical Oncology - Gastro
Intestinal conference) 15-17 January 2009 positive data from a phase Ib/II
study with belinostat and 5-fluorouracil (FU) for patients with colorectal
cancer were presented. The study has established that belinostat and 5-FU can
be safely given together in full doses . 35 previously heavily treated patients
with progressed solid tumors, whereof most suffered from colorectal cancer,
have been treated. Of these heavily treated patients 9 (26%) obtained
stabilisation of their disease. Preclinical studies indicate synergy between
belinostat and 5-FU and this clinical study supports this assumption in
patients' blood and cancer tissue. 

“It is very promising that 5-FU can be administered in full dose in combination
with full dose belinostat. 5-FU is one of the most used anticancer agents for
the treatment of colorectal and breast cancer. In this study we see belinostat
affecting the biochemistry in the patient's cancer cells, in the same way as we
see it in the laboratory. If these data hold, we should be able target those
patients with the largest potential for gaining effect of the treatment.” said
Professor Peter Buhl Jensen, MD, CEO of TopoTarget. “These patients were very
heavily pre-treated with 5-FU why and in several cases a long stabilisation
period of the cancer was observed. Combinations of belinostat and 5-FU should
be further evaluated in patients with less advanced pre-treatment, where one
would normally observe a higher number of patients with objective response”.
Peter Buhl Jensen further commented. 

For further information, please contact:

Peter Buhl Jensen 	  Telephone	+45 39 17 83 92
CEO		  Mobile	         +45 21 60 89 22

For further information about TopoTarget please visit www.topotarget.com